Wells Fargo lowered the firm’s price target on Boston Scientific (BSX) to $94 from $125 and keeps an Overweight rating on the shares. The firm notes the company reported a disappointing Q4 as U.S. EP and Watchman missed. Wells believes that Boston’s 2026 organic sales growth guidance of 10.0%-11.0% is doable as its estimates the company can grow 7.3% ex-EP, and EP can add 290bp.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $99 from $112 at Goldman Sachs
- Boston Scientific price target lowered to $100 from $115 at TD Cowen
- Boston Scientific price target lowered to $101 from $118 at Baird
- Boston Scientific price target lowered to $120 from $140 at UBS
- Boston Scientific price target lowered to $102 from $130 at Citi